OBJECTIVE/ BACKGROUND: Little is known about the epidemiology and the management of liver metastases from colorectal cancer at a population level. The aim of this population-based study was to report on the incidence, treatment, and prognosis of synchronous and metachronous liver metastases. METHODS: Data were obtained from the population-based cancer registry of Burgundy (France). RESULTS: The proportion of patients with synchronous liver metastases was 14.5%. Age-standardized incidence rates were 7.6 per 100,000 in males, 3.7 per 100,000 in females. The 5-year cumulative metachronous liver metastasis rate was 14.5%. It was 3.7% for TNM stage I tumors, 13.3% for stage II, and 30.4% for stage III (P < 0.001). The risk of liver metastasis was also associated to gross features. Resection for cure was performed in 6.3% of synchronous liver metastases and 16.9% of metachronous liver metastases. Age, presence of another site of recurrence, and period of diagnosis were independent factors associated with the performance of a resection for cure. The 1- and 5-year survival rates were 34.8% and 3.3% for synchronous liver metastases. Their corresponding rates were, respectively, 37.6% and 6.1% for metachronous liver metastases. CONCLUSION: Liver metastases from colorectal cancer remain a substantial problem. More effective treatments and mass screening represent promising approaches to decrease this problem.
OBJECTIVE/ BACKGROUND: Little is known about the epidemiology and the management of liver metastases from colorectal cancer at a population level. The aim of this population-based study was to report on the incidence, treatment, and prognosis of synchronous and metachronous liver metastases. METHODS: Data were obtained from the population-based cancer registry of Burgundy (France). RESULTS: The proportion of patients with synchronous liver metastases was 14.5%. Age-standardized incidence rates were 7.6 per 100,000 in males, 3.7 per 100,000 in females. The 5-year cumulative metachronous liver metastasis rate was 14.5%. It was 3.7% for TNM stage I tumors, 13.3% for stage II, and 30.4% for stage III (P < 0.001). The risk of liver metastasis was also associated to gross features. Resection for cure was performed in 6.3% of synchronous liver metastases and 16.9% of metachronous liver metastases. Age, presence of another site of recurrence, and period of diagnosis were independent factors associated with the performance of a resection for cure. The 1- and 5-year survival rates were 34.8% and 3.3% for synchronous liver metastases. Their corresponding rates were, respectively, 37.6% and 6.1% for metachronous liver metastases. CONCLUSION:Liver metastases from colorectal cancer remain a substantial problem. More effective treatments and mass screening represent promising approaches to decrease this problem.
Authors: G Gatta; R Capocaccia; M Sant; C M Bell; J W Coebergh; R A Damhuis; J Faivre; C Martinez-Garcia; J Pawlega; M Ponz de Leon; D Pottier; N Raverdy; E M Williams; F Berrino Journal: Gut Date: 2000-10 Impact factor: 23.059
Authors: S R Bramhall; U Gur; C Coldham; B K Gunson; A D Mayer; P McMaster; D Candinas; J A C Buckels; D F Mirza Journal: Ann R Coll Surg Engl Date: 2003-09 Impact factor: 1.891
Authors: Antonino Cavallari; Marco Vivarelli; Roberto Bellusci; Roberto Montalti; Nicola De Ruvo; Alessandro Cucchetti; Antonio De Vivo; Emilio De Raffele; MariaCristina Salone; Giuliano La Barba Journal: Hepatogastroenterology Date: 2003 Nov-Dec
Authors: Sanghui Park; Yun Soo Kim; Yu Jin Kim; Sun Young Kyung; Jeong-Woong Park; Sung Hwan Jeong; Sang Pyo Lee Journal: Dig Dis Sci Date: 2011-08-11 Impact factor: 3.199
Authors: Christopher R Shubert; Elizabeth B Habermann; John R Bergquist; Cornelius A Thiels; Kristine M Thomsen; Walter K Kremers; Michael L Kendrick; Robert R Cima; David M Nagorney Journal: J Gastrointest Surg Date: 2015-08-04 Impact factor: 3.452
Authors: Lauren S Tufts; Emma D Jarnagin; Jessica R Flynn; Mithat Gonen; Jose G Guillem; Philip B Paty; Garrett M Nash; Joshua J Smith; Iris H Wei; Emmanouil Pappou; Michael I D'Angelica; Peter J Allen; T Peter Kingham; Vinod P Balachandran; Jeffrey A Drebin; Julio Garcia-Aguilar; William R Jarnagin; Martin R Weiser Journal: HPB (Oxford) Date: 2018-08-01 Impact factor: 3.647